Industry-leading patient reimbursement solution reaches milestone of 3 million transactions, totaling more than $200 million in patient reimbursements worldwide
King of Prussia, PA – April 5, 2016 – Greenphire, the global leader in clinical payment solutions, today announced that it has made more than 3 million patient reimbursements through its ClinCard solution, automating payments of more than $200 million to clinical trial participants around the world.
According to the Center for Information and Study on Clinical Research Participation (CISCRP), the top factor that motivates study volunteers to continue to participate in a clinical research study is reimbursement.
Greenphire’s ClinCard is the only patented payment technology designed to simplify clinical trial reimbursement and provide a patient-centric experience. ClinCard is a reloadable debit card that is easy to use and accepted worldwide. The ClinCard solution, which streamlines the entire patient reimbursement process, has been used by thousands of research sites to reimburse nearly 400,000 patients across more than 25 countries.
“Our ClinCard solution was designed with the unique perspective that automating patient reimbursement can bring a significant improvement to the clinical trial experience for everyone involved – from the sponsor to the patient,” said Jim Murphy, CEO of Greenphire. “This focus on optimizing the clinical trial experience through automated payment solutions has resulted in long-term strategic partnerships with CROs, sponsors and research sites around the world.”
The easy-to-use ClinCard portal allows participants to receive reminders for upcoming appointments related to the trial. Additionally, through the ClinCard Travel Module, study participants are able to travel for the study without incurring out-of-pocket cost, further eliminating any hurdles that may keep the patient from participating in the study.
ClinCard also provides research sites a complete audit trail of all global payments, while maintaining blinded patient identities. This unprecedented visibility provides access to patient payment data for comprehensive and compliant financial analytics to streamline the reporting process, particularly for 1099 reports.
According to eyeforpharma, 85 percent of pharmaceutical executives agree that patient-centricity is the best route to clinical trial success. As a result, sponsors, CROs and research sites are looking to adopt new technologies that support clinical trial participation and engagement.
“Our ability to develop innovative solutions to extend and improve the lives of people with Cystic Fibrosis (CF) rests in our ability to efficiently run clinical studies,” said Rob Hopkins, Senior Director of Clinical Operations, Nivalis Therapeutics (Nasdaq: NVLS). “The ClinCard solution has played a significant role in our speed to develop N91115, by optimizing the clinical trial experience for our site partners, study participants and their caregivers.”
For more information on ClinCard or to schedule a demo of the solution, please visitwww.greenphire.com/contact.
About Greenphire
Greenphire is the leader in global clinical trial payment solutions. Greenphire’s best-in-class solutions optimize clinical trial performance by simplifying and streamlining payment processes from sponsors and CROs to sites and patients. Greenphire’s ClinCard and eClinicalGPS solutions easily handle any type of trial design and complexity, resulting in more accurate and compliant payments globally for both sites and patients. The choice of industry leaders worldwide, Greenphire provides better performance and better data, resulting in better trials. Learn more atwww.greenphire.com.
